Lexeo Therapeutics to present interim data from Phase 1/2 trial of LX1001

Lexeo Therapeutics (LXEO) announced that interim data from the ongoing Phase 1/2 trial of LX1001 have been selected as a late-breaking oral presentation at the Clinical Trials on Alzheimer’s Disease conference taking place October 29 – November 1, 2024, in Madrid, Spain. The presentation will include new safety and biomarker data from four dose cohorts of LX1001, an AAVrh10-based gene therapy candidate designed to deliver the protective APOE2 gene into the central nervous systems of APOE4 homozygotes with Alzheimer’s disease. The Phase 1/2 clinical trial is an open-label, dose-ranging study evaluating the safety and tolerability of LX1001 in fifteen patients with Alzheimer’s disease and two copies of the APOE4 allele. Study enrollment was completed in Q4 2023. The presentation will review safety as well as multiple measures of efficacy, including protein expression and tau and amyloid biomarkers. 12-month data will be presented for all patients in Cohorts 1-3, and 6-month data for Cohort 4.